Junxin Startup Company v. Green Valley Weiye Company, etc.
(Dispute over a Contract on Capital Contribution)@#
Judgment Abstract:@#
Where the plaintiff and defendant respectively submitted contradictoryevidence regarding the same fact, but neither had sufficient basis to rebut theevidence submitted by the other party, the party with the burden of proofshould take the consequence of failure of evidence.

Civil Judgment of the Supreme People's Court@#
No. 260 (2004)@#
@#
BASIC FACTS@#
Appellant (Plaintiff of the First Instance): Ningxia Junxin Startup Co., Ltd., domiciled at Room 101, No. 7, Science and Technology Street, Yinchuan Development Area, Ningxia Hui Autonomous Region.@#
Legal Representative: Hou Yuqian, board chairman of the company.@#
Authorized Agent: Wang Lei, lawyer of Jin Tian Ping Law Firm.@#
Respondent (Defendant of the First Instance): Shanghai Green Valley Weiye Ecological Engineering Co., Ltd., domiciled at Room 2615, No. 1688, Sichuan North Road, Shanghai City.@#
Legal Representative: Wu Tongxin, board chairman of the company.@#
Authorized Agent: Wang Junling, lawyer of Shanghai Jingcheng Law Firm.@#
The Third Party of the First Instance: Ningxia Protec Pharmaceutical Industry Share Limited Company, domiciled to the south of Road No. 4 and west of Road No. 15 in Yinchuan Hi-tech Development Area, Ningxia Hui Autonomous Region.@#
Legal Representative: Wang Zhongxiao, board chairman of the company.@#
Authorized Agent: Ding Liang, lawyer of Shanghai Guangming Law Firm.@#
Ningxia Junxin Startup Capital Co., Ltd. (hereinafter referred to as Junxin Company), the appellant, was dissatisfied with the Civil Judgment No. 17 (2003) of the Higher People's Court of Ningxia Hui Autonomous Region (hereinafter referred to as Ningxia Higher Court) regarding the dispute with Shanghai Green Valley Weiye Ecological Engineering Co., Ltd. (defendant of the first instance, hereinafter referred to as Green Valley Weiye Company) and Ningxia Protec Pharmaceutical Industry Share Limited Company (third person of the first instance, hereinafter referred to as Protec Pharmaceutical Industry Company) over the contract on capital contribution, and appealed to this Court. This Court formed a collegial panel composed of Wu Qingbao as the chief judge, and Gong Bangyou and Liu Min as acting judges, and heard the case. Zhao Suijun, the court clerk, made the hearing transcripts. The case has now been finalized.@#
It was verified by Ningxia Higher Court through hearing that, in June, 1998, Ningxia Institute of Materia Medica (hereinafter referred to as the Institute of Materia Medica) and Shanghai Green Valley Group jointly invested to establish Ningxia Orient Magical Grass Pharmaceutical Manufacturing Co., Ltd., which had a registered capital of 10 million Yuan. The Institute of Materia Medica contributed 7 million Yuan in kind), and Shanghai Green Valley Group Company contributed 3 million Yuan (including 1.6 million Yuan cash and 1.4 million Yuan in kind). In August the same year, Ningxia Orient Magical Grass Pharmaceutical Manufacturing Co., Ltd. was renamed as Ningxia Green Valley Pharmaceutical Manufacturing Co., Ltd. In March 2000, Shanghai Green Valley Group assigned all the shares and equities it held in Ningxia Green Valley Pharmaceutical Manufacturing Company to Green Valley Weiye Company. On August 1, 2000, the shareholders' meeting of Ningxia Green Valley Pharmaceutical Manufacturing Company adopted a resolution to increase its registered capital and issue more shares, whereby its registered capital rose up to 38 million Yuan. It was decided that the Institute of Materia Medica make an additional contribution of 12 million Yuan of capital, and Green Valley Weiye Company, 16 million Yuan. After the capital increase, the Institute of Materia Medica and Green Valley Weiye Company respectively occupied 50% of the shares of Ningxia Green Valley Pharmaceutical Manufacturing Company; the newly increased capital should be fully paid by installments before September 30, 2000. On September 6, 2000, the shareholders' meeting of Ningxia Green Valley Pharmaceutical Manufacturing Company adopted a resolution to approve the Institute of Materia Medica's assignment of all the 19 million Yuan of shares it held in Ningxia Green Valley Pharmaceutical Manufacturing Company. Among these shares, 2 million Yuan was assigned to Junxin Company, and 1 million Yuan was assigned to Inner Mongolia Linhe Xingke Pharmaceutical Co., Ltd. The shareholders' meeting also consented to Green Valley Weiye Company's assignment of partial shares, among which 3 million Yuan was assigned to Beijing Dadi Science and Technology Industry General Company, 1 million Yuan was assigned to Beijign Junyi Runtai Investment Consulting Co., Ltd., and 2 million Yuan was assigned to Shanghai Beirong Asset Management Co., Ltd. The former shareholders unanimously agreed to waive their pre-emptive rights in this assignment of shares. In October 2000, all the abovementioned parties concluded a “Company Promoters Agreement”, stipulating that, 1. Ningxia Green Valley Pharmaceutical Manufacturing Company should be renamed as Protec Pharmaceutical Industry Company; 2. Each promoter should perform its capital contribution obligation within 10 days after the said modification was approved; 3. The company's registered capital should be modified into 38 million Yuan; 4. If any promoter failed to contribute its capital within the time limit and according to the amount stipulated in the Agreement, this promoter in breach should pay a penalty for breach to the compliant parties at 0.5% of the payable portion of capital in breach for each day, and the compliant parties should distribute this penalty for breach according to the proportions of their respective capitals. The 16 million Yuan of shares newly added to Green Valley Weiye Company include 15 sums. The time of investments was between September 24, 1999 and September 18, 2000. Among these investments, those remitted by Ningxia Green Valley Pharmaceutical Industry Company amounted to 7,870,000 Yuan, and the remaining ones were remitted from the relevant accounts of Green Valley Weiye Company, totaling 16 million Yuan. Protec Pharmaceutical Industry Company issued receipts of capital contribution to Green Valley Weiye Company accordingly. Later, the Institute of Materia Medica and Green Valley Weiye Company practically accomplished the assignment of shares. Both Ningxia Green Valley Pharmaceutical Manufacturing Company and the present Protec Pharmaceutical Industry Company acknowledged that Green Valley Weiye Company's 16 million Yuan of capital had been fully contributed. As verified by the capital verification institution, each shareholder's capital had been fully contributed. Then the capital verification institution issued a capital verification report, and the new company was registered in the administrative organ for industry and commerce.@#
．．．．．．

君信创业公司诉绿谷伟业公司等出资合同纠纷案@#
【裁判摘要】@#
双方当事人对同一事实分别举出相反的证据，但均没有足够的依据否定对方证据的，对案件事实负有举证责任的当事人，应承担举证不力的责任。@#
中华人民共和国最高人民法院@#
民事判决书@#
(2004)民二终字第260号@#
上诉人(原审原告)：宁夏君信创业投资有限公司。住所地：宁夏回族自治区银川市开发区科技街7号101室。@#
法定代表人：侯羽乾，该公司董事长。@#
委托代理人：王磊，金天平律师事务所律师。@#
被上诉人(原审被告)：上海绿谷伟业生态工程有限公司。住所地：上海市四川北路1688号2615室。@#
法定代表人：吴同新，该公司董事长。@#
委托代理人：汪峻岭，上海市精诚律师事务所律师。@#
原审第三人：宁夏博尔泰力药业股份有限公司。住所地：宁夏回族自治区银川市高新技术开发区4号路南15号路西。@#
法定代表人：王忠效，该公司董事长。@#
委托代理人：丁亮，上海市光明律师事务所律师。@#
上诉人宁夏君信创业投资有限公司(以下简称君信公司)为与被上诉人上海绿谷伟业生态工程有限公司(以下简称绿谷伟业公司)及原审第三人宁夏博尔泰力药业股份有限公司(以下简称博尔泰力药业股份公司)出资合同纠纷一案，不服宁夏回族自治区高级人民法院(2003)宁民商初字第17号民事判决，向本院提起上诉。本院依法组成由审判员吴庆宝担任审判长，代理审判员宫邦友、刘敏参加的合议庭进行了审理，书记员赵穗军担任记录。本案现已审理终结。@#
原审法院经审理查明，1998年6月，由宁夏药物研究所(以下简称药研所)、上海绿谷集团共同投资组建成立了宁夏东方神草制药有限公司，注册资本1000万元，药研所出资700万元(以实物折价投资)；上海绿谷集团公司出资300万元(货币160万元、实物原料折价140万元)。同年8月，宁夏东方神草制药有限公司更名为宁夏绿谷制药有限公司。2000年3月，上海绿谷集团将其持有的宁夏绿谷制药公司的全部股份及其全部权益转让给绿谷伟业公司。2000年8月1日，宁夏绿谷制药公司股东会议决议增资扩股，将宁夏绿谷制药公司注册资本增加至3800万元。决定：药研所增资1200万元，绿谷伟业公司增资1600万元；增资后，药研所与绿谷伟业公司各占宁夏绿谷制药公司50％的股份；新增出资应于2000年9月30日前分批缴足。2000年9月6日，宁夏绿谷制药公司股东会议决议，同意药研所将其持有的宁夏绿谷制药公司的1900万元股份全部转让，其中200万元转让给原告君信公司，100万元转让给内蒙古临河兴科药业有限公司。同意绿谷伟业公司转让部分股份，其中300万元转让给北京市大地科技实业总公司，100万元转让给北京君益润泰投资咨询有限公司，200万元转让给上海北融资产管理有限公司。原股东一致同意放弃本次股份转让的优先认购权。2000年10月，上述各方订立了《发起人协议》，约定：1．将宁夏绿谷制药公司变更为博尔泰力药业股份公司；2．各发起人需在公司变更批准后10日内履行出资义务；3．公司注册资本3800万元；4．发起人未按本协议规定的期限、数额缴纳出资，每违约一天，违约方应缴付其违约部分出资额的千分之五作为违约金给履约方，该违约金依履约方出资比例分配。绿谷伟业公司新增扩股的1600万元，共有15笔的记载。投资的时间是1999年9月24日至2000年9月18日。其中由宁夏绿谷药业公司汇出代为投资的计787万元。其余为绿谷伟业公司相关账户汇出。合计1600万元。博尔泰力药业股份公司向绿谷伟业公司出具了相应的出资收据。随后，药研所、绿谷伟业公司实际完成了股份转让。宁夏绿谷制药公司及现在的博尔泰力药业股份公司均承认绿谷伟业公司投资1600万元已经实际到位。经验资机构验证，各股东出资已到位，出具了验资报告，并经工商机关进行了登记注册。@#
另查明，1997年2月，上海绿谷集团公司与药研所共同投资组建成立了宁夏绿谷药业公司，现更名为宁夏博尔泰力药业营销有限公司(以下简称营销公司)。上海绿谷集团公司以实物折价400万元和货币资金50万元出资；药研所以实物折价50万元出资，公司注册资本为500万元。1998年12月，宁夏绿谷药业公司增资扩股，将注册资本增至1000万元，其中上海绿谷集团公司占700万元，药研所占300万元。由上海绿谷集团公司控股。2000年3月，上海绿谷集团公司将其在宁夏绿谷药业公司的股份全部转让给绿谷伟业公司。2000年9月，宁夏绿谷制药公司(即母公司)完成增资扩股后，上海绿谷伟业公司和药研所将宁夏绿谷药业公司(即子公司)90％的股份转让给宁夏绿谷制药公司。绿谷伟业公司和药研所各保留5％的股份。2003年10月21日，君信公司以绿谷伟业公司出资不实为由起诉至原审法院，请求判令其向君信公司承担违约责任，保护合法权益不受侵犯。@#
@#
宁夏回族自治区高级人民法院认为，本案争议的焦点是：绿谷伟业公司是否存在虚假出资的事实。@#
@#
君信公司提供的主要证据《宁夏审计厅关于宁夏博尔泰力药业股份有限公司股权投资等有关问题的审计调查报告》，系宁夏回族自治区审计厅就宁夏博尔泰力药业股份有限公司中国有资产存在的问题，进驻宁夏博尔泰力药业股份有限公司进行审计调查后向宁夏回族自治区政府领导提交的内部审计调查报告，不符合民事诉讼证据的形式要件和鉴定结论的证据要求，不予采信。君信公司的其他证据只能证明绿谷伟业公司出资的具体形式和资金来源，君信公司与绿谷伟业公司在一审庭审过程中均不提出审计鉴定申请。该院认为绿谷伟业公司是否存在虚假出资行为涉及企业财务管理的专门性问题，按照最高人民法院《关于民事诉讼证据的若干规定》，根据君信公司在一审中提供的证据，无法认定绿谷伟业公司是否属于虚假出资。故君信公司的诉讼请求不能成立，该院依照《中华人民共和国民事诉讼法》第一百二十八条、最高人民法院《关于民事诉讼证据的若干规定》第二条第二款之规定，判决如下：一、驳回君信公司的诉讼请求；二、案件受理费87360元、保全费77870元，合计165230元，由君信公司承担。@#
．．．．．．